Redx – pharmaceutical daily

August 23, 2023 Off

FDA sees the potential of Redx Pharma’s zelasudil for treatment of Idiopathic Pulmonary Fibrosis

Redx has received Orphan Drug Designation from the US Food and Drug Administration (FDA) for the potential treatment of Idiopathic Pulmonary Fibrosis (IPF) for Zelasudil, which is currently in a Phase 2a clinical study for IPF, with topline data expected in Q1 2024.

September 8, 2016 Off

Redx CFO steps down, the company searches new one

By Dino Mustafić

Redx CFO steps down, the company searches new one

September 6, 2016 Off

Quay Pharma to formulate capsules to be be administered in Redx’s trial

By Dino Mustafić

Quay Pharma will be formulating the capsules that will be administered in Redx’s trial.

November 5, 2015 Off

Redx makes managerial changes

By Dino Mustafić

Redx, the drug discovery and development company, has made two senior management appointments.

The company on Thursday said that Nicholas Adams is new as Chief Business Officer and Dr Matilda Bingham has been promoted to Executive Director of Redx Oncology Ltd, the Group’s oncology subsidiary.